Comparison · NCT01931098-adaeefa2
Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure vs Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure vs Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Trial comparisons, record NCT01931098-adaeefa2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01931098-adaeefa2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.701 | 1 | wilson | |
| Risk in group 2 | 0.808 | 0.621 | 0.915 | wilson | |
| Risk difference, group 1 minus group 2 | 0.192 | -0.125 | 0.379 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.24 | 1.03 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure than on Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | 5.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure | Topotecan and pazopanib are administered orally daily.~topotecan: Taken .25 mg orally, daily continuous until progression up to one year.~pazopanib: 600 mg orally, daily until progression, up to one year. | 9 | 9 | OG000 |
| Group 2 | Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure | Topotecan and pazopanib are administered orally daily.~topotecan: Taken .25 mg orally, daily continuous until progression up to one year.~pazopanib: 600 mg orally, daily until progression, up to one year. | 21 | 26 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
- Description
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
- Time frame
- Date treatment consent signed to date off study, approximately 20 months and 18 days for the first Arm/Group, and 28 months and 23 days for the second Arm/Group.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- NCT number
- NCT01931098
- Phases
- PHASE2
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms, Central Nervous System Neoplasms
- Interventions
- topotecan, pazopanib
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2020-09-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01931098?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01931098-adaeefa2